ERBB2 somatic mutation
Tuesday 8 October 2013
ERBB2 somatic mutations
ERBB2/HER2, best known for its role in breast cancer tumorigenesis, can be targeted by two types of pharmacological manipulation: antibody therapy against the extracellular receptor domain and small molecule compounds against the intracellular tyrosine kinase domain.
The advent of next-generation sequencing technologies has enabled efficient identification of activating molecular alterations of ERBB2.
ERBB2 somatic mutations in
- pulmonary adenocarcinoma (MIM.211980)
- glioblastoma (MIM.137800)
- gastric adenocarcinoma (MIM.137215)
- ovarian carcinomas
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Felip E, Rouquette I, Milia JD, Gautschi O.
J Clin Oncol. 2013 Jun 1;31(16):1997-2003. doi : 10.1200/JCO.2012.45.609 PMID: 23610105